Aldeyra Therapeutics ALDX
NASDAQ ALDX
$1.23 -0.06 (-4.34%)
As of: Oct 2, 2026 · 9:40 AM EDT

Aldeyra Therapeutics (ALDX) Non Operating Interest Expenses (2013 - 2026)

Updated

Aldeyra Therapeutics (ALDX) recorded Non Operating Interest Expenses of $23.00 in Q2 2026, down 100.0% from $470,618 a year earlier and down 100.0% from the prior quarter.

Analysis

Aldeyra Therapeutics (ALDX) Non Operating Interest Expenses (2013 - 2026) Analysis & Trends

On a TTM basis, Aldeyra Therapeutics' Non Operating Interest Expenses came in at $1.42 million as of Jun 30, 2026, down 25.4% year-over-year; for FY2025, it came in at $1.91 million, down 1.1% from FY2024.

  • Annual Non Operating Interest Expenses has a five-year compound annual growth rate of 0.0% (FY2020 to FY2025).
  • Across earlier years, Non Operating Interest Expenses came in at $1.93 million in FY2024 (-7.0%), $2.07 million in FY2023 (+22.3%), $1.69 million in FY2022 (-2.8%) and $1.74 million in FY2021 (-8.5%).
  • The Q2 2026 figure is the lowest quarterly Non Operating Interest Expenses in data going back to Q1 2013.
  • On a year-over-year basis, Non Operating Interest Expenses rose in 1 of the last eight quarters, with an average decline of 15.8%.
  • Peak year-over-year performance for Non Operating Interest Expenses in the last five years was growth of 29.2% in Q3 2023, against a decline of 100.0% in Q2 2026 at the low end.
  • Per Business Quant, the preceding three quarters came in at $468,678 (Q1 2026), $475,259 (Q4 2025) and $475,903 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 281.00 Mn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -462.00 Mn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -435.00 Mn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 673.00 Mn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 247.00 Mn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Aldeyra Therapeutics 74.19 Mn 74.19 Mn - 23.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 23.00
Mar 31, 2026 468,678.00
Dec 31, 2025 475,259.00
Sep 30, 2025 475,903.00
Jun 30, 2025 470,618.00
Mar 31, 2025 483,529.00
Dec 31, 2024 470,863.00
Sep 30, 2024 479,252.00
Jun 30, 2024 477,601.00
Mar 31, 2024 498,526.00
Dec 31, 2023 514,264.00
Sep 30, 2023 538,743.00
Jun 30, 2023 527,141.00
Mar 31, 2023 491,287.00
Dec 31, 2022 460,819.00
Sep 30, 2022 416,917.00
Jun 30, 2022 410,395.00
Mar 31, 2022 405,967.00
Dec 31, 2021 412,935.00
Sep 30, 2021 413,110.00
API Access

Aldeyra Therapeutics Non Operating Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-interest-expenses&ticker=ALDX&period=max&api_key=YOUR_API_KEY